Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CS-001 · 1 trial · 2 indications
Greying Severity Score (GSS). Mild Greying score between 0-5, Moderate Greying score between 6-10 and Severe Greying score between 11-15
| Arm | Type | Description |
|---|---|---|
| CS-001 | EXPERIMENTAL | CS-001 Topical Treatment |
| Placebo | PLACEBO_COMPARATOR | Placebo Topical Treatment |
| Name | Type | Description |
|---|---|---|
| CS-001 | DRUG | CS-001 Topical Treatment |
| Placebo Topical Solution | DRUG | Placebo Topical Solution |
Inclusion Criteria: * Age 30 to 65 * Diagnosed with Grey Hair (Canities) * Willing and able to apply the treatment as directed, comply with study * Otherwise healthy * Able to give informed consent Exclusion Criteria: * A medical history that may interfere with study objectives * Women who are pr...
CS-001 is an investigational small molecule being developed for the treatment of canities, commonly known as grey hair. It is currently in Phase 3 clinical development and has not been approved by regulatory authorities.
CS-001 is being developed by Applied Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol APLT. The company is conducting a Phase 3 clinical trial to evaluate the drug's safety and efficacy in patients with canities.
CS-001 is currently in Phase 3 clinical development. It is an investigational drug and has not yet been approved by the FDA or any other regulatory agency. The ongoing Phase 3 trial is designed to assess its effectiveness in treating grey hair.
CS-001 is being evaluated in a Phase 3 clinical trial registered as NCT06745336. This randomized, double-blind, placebo-controlled study is not yet recruiting and aims to enroll approximately 240 participants aged 30 years and older with canities or grey hair.
No alternative names for CS-001 have been disclosed. It is a unique investigational compound developed by Applied Therapeutics, Inc. and is not known to be identical to any other marketed or investigational drug.